Blog - INTERNET MÉDICA

Doença Inflamatória Intestinal (Inflammatory Bowel Disease: BMC Gastroenterology 2022)

Por Paulo Leite 02/03/2023

■ Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

Ligia Yukie Sassaki, Daniela Oliveira Magro, Rogerio Saad-Hossne et al

GEDIIB (Brazilian Study Group of IBD)

BMC Gastroenterol. 2022; 22: 268

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150299/

■ Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis fator patients with Crohn´s disease: a real-world multicenter Brazilian study

Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz et al

BMC Gastroenterol. 2022; 22: 199.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027080/

■ Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agente after the failure of a first anti-TNF agente in patients with Crohn´s disease: a multicenter rerospective study

Rayer Cassandra, Maria Nachury, Bourreille Arnaudet et al

BMC Gastroenterol. 2022; 22: 498

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717550/

■ Female gender, dissatisfaction with weight, and number of IBD related surgeries as independente risk factors for eating disorders among patients with inflammatory bowel diseases

Gianna Stoleru, Andrew Leopold, Amanda Auerbach, Shelley Nehman, Uni Wong

BMC Gastroenterol. 2022; 22: 438

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578268/

■ Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study

Ellen Kuenzig, Douglas G. Manuel, Jessy Donelle, Eric I. Benchimol

BMC Gastroenterol. 2022; 22: 5

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728958/

■ Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with fofacitinib for moderate to severe ulcerative colitis

M V Chiorean, J R Allegretti, P P Sharma et al

BMC Gastroenterol. 2022; 22: 177

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994921/

■ Comparison the effects and side effects of COVID-19 vaccination in patients with inflammatory bowel

l disease (IBD): a systematic scoping review

Elham Tabesh, Maryam Soheilipour, Mohammad Rezaeisadrabadi, et al

BMC Gastroenterol. 2022; 22: 393

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392501/

■ Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe COVID-19 pneumonia: a case report

Lisanne Rieker, Johannes Hofer, Golo Petzold, et al

BMC Gastroenterol. 2022; 22: 22

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760596/

■ Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review

Zambrano-Sánchez, P. Alvarez-Mena, D. Hidalgo, et al

BMC Gastroenterol. 2022; 22: 447

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637309/

■ Ultrasonographic scores for ileal Crohn´s disease assessment: Better, worse or the same as contrast-enhanced ultrasound?

Freitas, F. Dias de Castro, V. Macedo Silva et al

BMC Gastroenterol. 2022; 22: 252

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118849/

■ Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease

Ken Lund, Michael Due Larsen, Torben Knudsen et al

BMC Gastroenterol. 2022; 22: 290

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171971/

■ Systematic review and meta-analysis: the advantage of endoscopic Mayo score o over 1 in patients with ulcerative colitis

Angelo Viscido, Marco Valvano, Gianpiero Stefanelli, et al

BMC Gastroenterol. 2022; 22: 92

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895505/

■ A systematic review of the patient burden of Crohn´s disease-related rectovaginal and anovaginal fistulas

Kristy Iglay, Dimitri Bennett, Michael D. Kappelman, et al

BMC Gastroenterol. 2022; 22: 36

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796404/

■ Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, et al

BMC Gastroenterol. 2022; 22: 71

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858477/

■ Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methrotrexate accumulation in Crohn´s disease: across-sectional study

M. van de Meeberg, M. L. Seinen, H. H. Fidder, et al

BMC Gastroenterol. 2022; 22: 365

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338675/

■ Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

V Jairath, R D Cohen, E V Loftus et al

BMC Gastroenterol 2022, vol 22: 501

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724317/

■ Multimorbidity among inflammatory bowel disease patients ina tertiary care centre: a retrospective study

M H Mosli, M Alsahafi, M N Alsanea et al

BMC Gastroenterol 2022, vol 22: 487

https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02578-2

■ Effects of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study

Seth R. Shaffer, Zoann Nugent, Charles N. Bernstein et al

BMC Gastroenterol. 2022; 22: 140

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962161/

■ Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study

Kay-Martin Johnsen, Jon Florholmen, Øystein K. Moe et al

BMC Gastroenterol. 2022; 22: 459

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667633/

■ Multimodal intervention to improve the transition of patients with inflammatory bowel disease from pediatric to adult care: protocol for a randomized controlled trial

Natasha Bollegala, Melanie Barwick, Nancy Fu et al

BMC Gastroenterol. 2022; 22: 251

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118697/

■ Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al

BMC Gastroenterol. 2022; 22: 291

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178865/

■ Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease

Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, et al

BMC Gastroenterol. 2022; 22: 464

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670620/

■ Medication use among patients with Crohn´s disease or ulcerative colitis before and after the initiation of advanced therapy

Theresa Hunter, April N. Naegeli, Chi Nguyen et al

BMC Gastroenterol. 2022; 22: 474

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675977/

■ Clustering of pediatric onset inflammatory bowel disease in Finland: a Nationwide register-based study

Atte Nikkilä, Anssi Auvinen, Kaija-Leena Kolho

BMC Gastroenterol. 2022; 22: 512

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743626/

■ Clustering of pediatric onset inflammatory bowel disease in Finland: a Nationwide register-based study

Atte Nikkilä, Anssi Auvinen, Kaija-Leena Kolho

BMC Gastroenterol. 2022; 22: 512

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743626/

■ Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Cronh´s disease

Michael Logan, Mary MacKinder, Clare Martha Clark et al

BMC Gastroenterol. 2022; 22: 260

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125891/

■ Emphysematous cystitis as a potential marker of severe Crohn´s disease

M. Mahmudul Hasan, Baljinder S. Salh

BMC Gastroenterol. 2022; 22: 181

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004142/

■ A case for improved assessment of gut permeability: a meta-analysis quantifying the lactulose: manitol ratio in coeliac and Crohn´s disease

Jonathan Gan, Scarlet Nazarian, Julian Teare, et al

BMC Gastroenterol. 2022; 22: 16

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751358/

■ Acesso gratuito

■ Um dos Blog de Medicina mais acessado em todo o mundo. Mais de 810 temas médicos já disponíveis online

■ Use o mecanismo de busca – PESQUISAR na home page.

■ Acesse ARQUIVO e encontre os temas incluídos no Blog a cada mês, desde maio 2017

■ Blog Internet Médica – www.internetmedica.com.br

■ Médico Responsável: Dr Paulo Fernando Leite

CRMMG: 7026

Belo Horizonte/MG/Brasil

Email: pfleite1873@gmail.com

Março 2023

Malária: BMC Medicine 2022

Por Paulo Leite 28/02/2023

■ Haematological consequences of acute uncomplicated falciparum malária: a WordWide Antimalarial Resistance Network pooled analysis of individual patient data

The WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

BMC Med. 2022; 20: 85

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900374/

■ Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Kasia Stepniewska, Elizabeth N. Allen, Georgina S. Humphreys et al

BMC Med. 2022; 20: 35

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479278/7

■ Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs

Dancan M. Wakoli, Bartholomew N. Ondigo, Douglas O. Ochora, et al

BMC Med. 2022; 20: 448

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673313/

■ Induction, decay, and determinants of functional antibodies following vaccination with the RTS.S malária vaccine in young children

Gaoqian Feng, Liriye Kurtovic, Paul A. Agius et al

BMC Med. 2022; 20: 289.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402280/

■ Intermittent screening and treatment for malária complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superioreity trial

Jeanne Rini Poespoprodjo, Hafiidhaturrahmah, Novita Sariyanti, et al

BMC Med. 2022; 20: 190.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175359/

■ Gravity and malária trends Interact to modify P. falciparum sensities and detectability in pregancy: a 3-year prospective multi-site observational study

Glória Matambisso, Nanna Brokhattingen, Sónia Maculuve et al

BMC Med. 2022; 20: 39

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664815/

■ Naturally acquired antovbody kinetics Against Plasmodium vivax antigens in people from a low malária transmission region in western Thailand

Zoe Shih-Jung Liu, Jetsumon Sattabongkot, Michael White et al

BMC Med. 2022; 20: 89

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904165/

■ Developing sero-diagnostic tests to facilitate Plamodium vivax serological test-and-treat approaches: modeling the balance between public health impact and overtreatment

Thomas Obadia, Narimane Nekkab, Leanne J. Robinson et al

BMC Med. 2022; 20: 98

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932240/

■ Malaria hospitalization in East Africa: age, phenotype and transmission intensity

Alice Kamau, Robert S. Paton, Samuel Akech, et al

BMC Med. 2022; 20: 28

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793189/

■ Proactive community case management decreased malária prevalence in rural Madagascar: results from a cluster randomized trial

Rila Ratovoson, Andres Garchitorena, Daouda Kassie et al

BMC Med. 2022; 20: 322.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531497/

■ The potential impact of Anopheles stephensi establisment on the transmission of Plasmodium falciparum in Ethiopia and prospective control measures

Arran Hamlet, Dereje Dengela, J. Eric Tongren, et al

BMC Med. 2022; 20: 135

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020030/

■ The duraton of protection Against clinical malária provided by the comination of seasonal RTS.S/AS01E vaccination and seasonal malária chemoprevention versus either intervention given alone

Matthew Cairns, Amadou Barry, Issaka Zongo et al

BMC Med. 2022; 20: 352

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540742/

■ Effectiveness of rectal artesunate as pre-referral treatment for severe malária in children under 5 years of age: a multi-country observational study

Manuel W. Hetzel, Jean Okitawutshu, Antoinette Tshefu et al

BMC Med. 2022; 20: 343

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550309/